Pharmacological rationale for antibiotic treatment of intra-abdominal infections

Journal of Chemotherapy

Volumn 21, Issue SUPPL. 1, 2009, Pages 19-29

  Mazzei, T ^a   Novelli, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Intra abdominal infections; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM; CEFAZOLIN; CEFODIZIME; CEFONICID; CEFOPERAZONE; CEFOTETAN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; DALFOPRISTIN PLUS QUINUPRISTIN; ERTAPENEM; GENTAMICIN; LINEZOLID; METRONIDAZOLE; MONOBACTAM DERIVATIVE; NETILMICIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PENICILLIN V; PHENETICILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CONTINUOUS INFUSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROCOCCAL INFECTION; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; RECOMMENDED DRUG DOSE; REVIEW; UNSPECIFIED SIDE EFFECT; DIGESTIVE SYSTEM DISEASE; INFECTION; MICROBIOLOGY;

ANTI-INFECTIVE AGENTS; DIGESTIVE SYSTEM DISEASES; HUMANS; INFECTION;

EID: 70350493084     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.supplement-1.19     Document Type: Review

References (77)

1. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 Suppl 2: 17-25.
2. Craig WA. Selecting the antibiotic. Proc Symposium Sonoma 1993: 28(Suppl 1): 26-27/1.
3. Craig WA, Gudmundsson S. Postantibiotic effect. In: Antibiotics in Laboratory Medicine. (Lorian , Eds). 1991:403.
4. Craig WA. Post-antibiotic effects in experimental infection models; relationship to in vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993;31(Suppl D): 149-158.
5. Mazzei T, Novelli A, Mini E, Periti P. Concentrazioni plasmatiche e tissutali degli antibiotici: qual è il loro valore predittivo? Ann Ital Med Int 1992;7(suppl 3): 67-73.
6. Rinaldi S, Novelli A, De Gaudio AR. Systemic antibiotics, In: Infection Control in Intensive Care Unit, (van Saene HKF, Silvestri L, de la Cal, M.A. Eds.), Springer Verlag 2nd ed., 2005.
7. Andes D. Pharmacokinetics and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2001; 14:165-172.
8. Craig WA. Pharmacokinetics/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
9. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9(Suppl. 3): 38-44.
10. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials. J Am Med Assoc 1998; 279: 125-129.
11. Moore RD, Lietman PS, Smith CR. Clinical response of aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155(1): 93-99.
12. Weinstein MP, Stratton CW, Hawley HB, et al. Multicenter collaborative evaluation of standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med 1987; 83 (2): 218-222.
13. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
14. MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998; 20(5): 473-477.
15. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-527.
16. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003; 17(3): 529-543.
17. Schentag JJ, Gilliland KK, Paladino A. What we have learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001; 32(Suppl. 1): 39-46.
18. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255-259.
19. De Ryke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 2006; 66(1): 1-14.
20. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/ pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28(2): 143-160.
21. Bassi C, Pederzoli P, Vesentini S et al. Behavior of antibiotics during human necrotizing pancreatitis. Antimicrob Agents Chemother 1994;38(4): 830-6.
22. Buchler M, Malfertheiner P, Friess H et al. Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology 1992; 103(6): 1902-8.
23. Serour F, Dan M, Gorea A, Gilad A, Krispin M, Berger SA. Penetration of aminoglycosides into human peritoneal tissue. Chemotherapy 1990; 36(4): 251-3.
24. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45(6):753-60.
25. Dorman T, Swoboda S, Zarfeshenfard F, et al. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group. Surgery 1998; 124(1): 73-78.
26. Hansen M, Ghristrup LL, Jarlov JO, et al. Gentamicin dosing in critically ill patients. Acta Anaesthesiol Scand 2001; 45(6): 734-740.
27. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41(14): 1135-1151.
28. Hermann T. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci. 2007;64(14):1841-52.
29. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840-51.
30. Mandell GL, Bennett JE, Kolin R. (Eds). Principles and Practice of Infectious Diseases. Churchill Livingstone, Philadelphia, PA. 2000.
31. Freeman CD, Nicolau DP, Belliveau PP et al. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39: 677-686.
32. Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 2003; 114: 194-198.
33. Winston L, Benowitz N. Once-daily dosing of aminoglycosides: how much monitoring is truly required? Am J Med 2003; 114: 239-240.
34. Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006; 57: 639-647.
35. Houang ET, Colley N, Chapman M. Penetration of sulbactam-ampicillin and clavulanic acid-amoxicillin into the pelvic peritoneum. Antimicrob Agents Chemother 1985; 28(1): 165-6.
36. Hary L, Smail A, Ducroix JP, Baillet J, Andrejak M. Pharmacokinetics and ascitic fluid penetration of piperacillin in cirrhosis. Fundam Clin Pharmacol 1991; 5(9): 789-95.
37. Drewelow B, Koch K, Otto C, Franke A, Riethling AK. Penetration of ceftazidime into human pancreas. Infection 1993; 21(4): 229-34.
38. Corbett CR, McFarland RJ, Spender GR, Ryan DM. The penetration of ceftazidime into peritoneal fluid in patients undergoing elective abdominal surgery. J Antimicrob Chemother 1985; 16(2): 261-5.
39. Martin C, Cottin A, Francois-Godfroy N, et al. Concentrations of prophylactic ceftriaxone in abdominal tissues durino pancreatic surgery. J Antimicrob Chemother 1997;40(3):445-8.
40. Delcenserie R, Dellion-Lozinguez MP, Yzet T, et al. Pancreatic concentrations of cefepime. J Antimicrob Chemother 2001; 47(5): 711-3.
41. Okamoto MP, Chin A, Gill MA, et al. Analysis of cefepime tissue penetration into human appendix. Pharmacotherapy 1991; 11(5): 353-8.
42. Lowe MN, Lamb HM. Meropenem: an updated review of its use in the management of intra-abdominal infections. Drugs 2000; 60(3): 619-46.
43. Wittau M, Wagner E, Kaever V, Koal T, Henne-Bruns D, Isenmann R. Intraabdominal tissue concentration of ertapenem. J Antimicrob Chemolher 2006; 57(2): 312-6.
44. Arrigucci S, Garcea A, Fallani S, et al. Ertapenem peritoneal fluid concentrations in adult surgical patients. Int J Antimicrob Agents 2009; 33(4): 371-3.
45. Petri WA Jr. Penicillins, cephalosporins, and other -lactam antibiotics, In The pharmacological basis of therapeutics. Eleventh Edition. (Goodman & Gilman's Eds), McGraw-Hill: 2006; 1127-1154.
46. Mazzei T, Mini E, Novelli A. Rilevanza clinica del legame proteico degli antibiotici con particolare riferimento alle betalattamine cefemiche. Giorn It Chemioter 1994; 41:79 89.
47. 47du Souich P, Verges J, Erill S. Plasma protein binding and pharmacological response. Clin Pharmacokinet 1993; 24 (6): 435-440.
48. Bakker-Woundenberg IA, Roosendaal R. Impact of dosage schedule of antibiotics on the treatment of serious infections. Intensive Care Med 1990; 16(Suppl 3): S229-S234.
49. Gomez CM, Cordingly JJ, Palazzo MG. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob. Agents Chemother 1999; 43: 1798-1802.
50. Lipman J, Wallis SC, Richard CM, Fraenkel D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001;27:363-370.
51. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 2004; 53 Suppl 2: ii23-28.
52. Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005; 49(5): 1881-9.
53. Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Pharmacokinetic evaluation of meropenem and imipenem in critically-ill patients with sepsis. Clin Pharmacokinet 2005; 44(5): 539-549.
54. Solomkin JS, Mazuski JE, Baron EJ, et al. Infectious Diseases Society of America. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37(8): 997-1005.
55. Rybak M. Pharmacodynamics: relation to antimicrobial resistance. Am J Med 2006; 119(6 Suppl 1): S37-44, discussion S62-70.
56. Edmiston CE Jr, Suarez EC, Walker AP, et al. Penetration of ciprofloxacin and fleroxacin into biliary tract. Antimicrob Agents Chemother 1996; 40(3): 787-91.
57. Swoboda S, Oberdorfer K, Klee F, Hoppe-Tichy T, von Baum H, Geiss HK. Tissue and serum concentrations of levofloxacin 500 mg administered intravenously or orally for antibiotic prophylaxis in biliary surgery. J Antimicrob Chemother 2003; 51(2): 459-62.
58. Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58(3): 693-6.
59. Pickerill KE, Paladino JA, Schentag JJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy 2000; 417-28.
60. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000; 232(2): 254-62.
61. Wacha H, Warren B, Bassaris H, Nikolaidis P. The Intra-Abdominal Infections Study Group. Comparison of sequential intravenous/ oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections. Surg Infect (Larchmt) 2006; 7(4): 341-54.
62. Mazzei T. Parametri di valutazione per una corretta terapia con glicopeptidi nel paziente critico - L'opinione dell'esperto. Challenges in Medical Science, Edizioni Élite Communication Sri, Milano 2002.
63. Di Filippo A, De Gaudio AR, Novelli A, et al. Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. Chemotherapy 1998; 44(1): 63-8.
64. Wilson AP. Clinical Pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000; 39(3): 167-183.
65. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001; 61(4): 525-551.
66. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-10.
67. Bearden DT. Clinical pharmacokinetics of quinupristin/ dalfopristin. Clin Pharmacokinet 2004; 43(4): 239-52.
68. Edwards DI. Nitroimidazoles, In: Antibiotics and Chemotherapy. (Finch RG, Greenwood D.Norrby SR, Whitley RJ Eds). Churchill Livingstone 8th Ed. 2003.
69. Scheetz MH, Reddy P, Nicolau DP, et al. Peritoneal fluid penetration of tigecycline. Ann Pharmacother 2006; 40(11): 2064-7.
70. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64 (1): 63-88.
71. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerabilily of tigecycline. J Chemother 2005;17 Suppl 1:12-22.
72. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005; 25(3): 185-92.
73. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSl Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5, S341-53.
74. Babinchak T, Ellis-Grosse EJ, Dartois N, Rose GM, Loh E. Tigecycline 301 Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354-67.
75. Fomin P, Koalov S, Cooper A, et al. 301 and 306 Study Groups. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience. J Chemother 2008; 20(suppl 1): 12-19.
76. Teras J, Gardovskis J, Vaasna T et al. 305 Study Group: Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective. J Chemother 2008; 20(suppl 1): 20-27.
77. Bamberger DM, Foxworth JW, Bridwell DL, Shain CS, Gerding DN. Extravascular antimicrobial distribution and the respective blood and urine concentrations in humans. In: V. Lorian, ed. Antibiotics in Laboratory Medicine. Philadelphia: Lippincott Williams & Wilkins. 2005: 719-814.